Detection and quantification of mutations in the plasma of patients with colorectal tumors.

By F. Diehl, M. Li, D. Dressman, Yiping He, D. Shen, Steve Szabo, L. Diaz, Steven N. Goodman, K. David, H. Juhl and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2005

1,170 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0a67ce4db729cd3873e13a4ad0ea2f378af05e12

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Bardelli
2. L. Diaz
3. Daniel C. Koboldt
4. Elaine R. Mardis
5. Jerzy K. Kulski
6. K. Pantel
7. C. Alix‐Panabières

In Molecular Biology

1. Richard K. Wilson
2. Elaine R. Mardis
3. Daniel C. Koboldt
4. L. Diaz
5. A. Bardelli
6. Fortunato Ciardiello
7. Jerzy K. Kulski
8. Richard J. Haier

In Pathology and Forensic Medicine

1. A. Bardelli
2. L. Diaz
3. Daniel C. Koboldt

Citations in the corpus

• Circulating tumor DNA as a liquid biopsy for cancer. (2015, background): “suggested that DNA fragments found in the circulation are derived from necrotic neoplastic cells that had been engulfed by macrophages (19).”
• Origins, structures, and functions of circulating DNA in oncology (2016, background): “Large cohorts of patients for screening of point mutations by cirDNA analysis [26]”
• Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, methodology): “01%).(10,11) RAS testing was carried out by a contract research organization (Sysmex Inostics, Hamburg, Germany).”
• Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients (2015, background): “Studies have reported the presence of longer DNA in the plasma of cancer patients (22–25), whereas others reported higher prevalence of cancer-associated DNA mutations among the shorter plasma DNA molecules (14, 27, 40).”
• The Next-Generation Sequencing Revolution and Its Impact on Genomics (2013, positive): “Hence, the ability to detect these changeswith high sensitivity poses an interesting and potentially powerful disease-monitoring capability that likely would complement imaging modalities such as CT or MRI but at much lower cost and with lower associated morbidities (Diehl et al., 2005; Diehl et al.”